John A. Glaspy
#138,010
Most Influential Person Now
John A. Glaspy's AcademicInfluence.com Rankings
John A. Glaspyphilosophy Degrees
Philosophy
#7062
World Rank
#10218
Historical Rank
Logic
#4141
World Rank
#5397
Historical Rank

Download Badge
Philosophy
John A. Glaspy's Degrees
- Doctorate Medicine University of California, San Francisco
- Bachelors Biological Sciences Stanford University
Why Is John A. Glaspy Influential?
(Suggest an Edit or Addition)John A. Glaspy's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- PD-1 blockade induces responses by inhibiting adaptive immune resistance (2014) (4971)
- Adjuvant trastuzumab in HER2-positive breast cancer. (2011) (1199)
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. (1998) (1107)
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer (1991) (1086)
- RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. (2011) (961)
- Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. (2014) (835)
- Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. (1997) (697)
- Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion (2003) (575)
- Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. (2009) (574)
- Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. (2005) (565)
- Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. (2002) (510)
- Thrombocytopenia caused by the development of antibodies to thrombopoietin. (2001) (493)
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. (2017) (426)
- Adjuvant Trastuzumab in HER 2-Positive Breast Cancer (2011) (383)
- A comparison of gene transfer methods in human dendritic cells. (1997) (333)
- Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. (2000) (320)
- Current developments in cancer vaccines and cellular immunotherapy. (2003) (300)
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. (2017) (295)
- Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. (2003) (289)
- PD-1 Blockade Expands Intratumoral Memory T Cells (2016) (288)
- Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. (1997) (282)
- Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. (2002) (277)
- Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. (2003) (267)
- Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. (1997) (265)
- Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. (1998) (262)
- Cancer Detection with Whole‐Body PET Using 2‐[18F]Fluoro‐2-Deoxy‐D-Glucose (1993) (254)
- Interferon‐α and granulocyte‐macrophage colony‐stimulating factor differentiate peripheral blood monocytes into potent antigen‐presenting cells (1998) (249)
- Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer (2010) (247)
- Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy (2002) (214)
- Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. (2011) (210)
- Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes (2010) (204)
- Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma (2009) (204)
- The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. (1992) (201)
- Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. (2013) (199)
- Use of complementary/alternative therapies by women with advanced-stage breast cancer (2002) (197)
- BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. (2012) (197)
- Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. (2008) (195)
- Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. (1997) (194)
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway (2011) (193)
- Clinical update: intravenous iron for anaemia (2007) (189)
- A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides (2006) (184)
- Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma (2014) (183)
- Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. (1988) (180)
- Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy (2002) (177)
- Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. (2002) (174)
- Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. (1999) (170)
- T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. (2003) (166)
- Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. (1998) (164)
- Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer (2018) (163)
- RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). (2009) (162)
- Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. (1997) (154)
- Effect of Altering Dietary ω-6/ω-3 Fatty Acid Ratios on Prostate Cancer Membrane Composition, Cyclooxygenase-2, and Prostaglandin E2 (2006) (153)
- Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. (2001) (148)
- Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. (1998) (142)
- Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. (2002) (140)
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans (2011) (139)
- Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. (2009) (137)
- Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. (1991) (137)
- Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. (2017) (136)
- A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. (2006) (133)
- α-Fetoprotein-specific Genetic Immunotherapy for Hepatocellular Carcinoma (1999) (133)
- Long-Chain n-3-to-n-6 Polyunsaturated Fatty Acid Ratios in Breast Adipose Tissue From Women With and Without Breast Cancer (2002) (126)
- Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade (2009) (123)
- T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human α Fetoprotein1 (2001) (120)
- Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma (2008) (119)
- Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment (2010) (119)
- Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. (2003) (119)
- Whole body skeletal imaging with [18F]fluoride ion and PET. (1993) (118)
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. (2019) (118)
- Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy (2004) (118)
- The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. (2003) (114)
- Imaging of pulmonary mass lesions with whole‐body positron emission tomography and fluorodeoxyglucose (1993) (113)
- Iron deficiency anemia--bridging the knowledge and practice gap. (2014) (112)
- Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. (2003) (110)
- Quantification of Glucose Utilization in Liver Metastases: Parametric Imaging of FDG Uptake with PET (1992) (107)
- p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. (1999) (106)
- A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. (2003) (104)
- alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. (2001) (103)
- Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. (1993) (102)
- A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. (1999) (102)
- Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy? (2009) (99)
- Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. (2010) (98)
- In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. (1996) (97)
- BRAF V600E inhibition in anaplastic thyroid cancer. (2013) (97)
- Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. (2006) (97)
- Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines† (2018) (95)
- Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. (2005) (95)
- Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer. (1997) (95)
- Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. (2000) (95)
- Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. (2002) (89)
- A randomized, active‐control, pilot trial of front‐loaded dosing regimens of darbepoetin‐alfa for the treatment of patients with anemia during chemotherapy for malignant disease (2003) (88)
- Cancer immunotherapy using gene-modified dendritic cells. (2002) (87)
- Therapeutic options in the management of renal cell carcinoma. (2002) (86)
- In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. (1997) (86)
- A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy (2001) (85)
- Integrated human T-cell leukemia virus II genome in CD8 + T cells from a patient with "atypical" hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders. (1988) (84)
- Heterogeneity of epidemic Kaposi's sarcoma. Implications for therapy (1986) (84)
- Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study (2016) (84)
- Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. (1999) (83)
- Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. (2006) (83)
- Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations (2011) (83)
- Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer (2001) (82)
- T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. (2001) (81)
- Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma (2008) (79)
- Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. (1995) (78)
- The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. (1993) (78)
- A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer (2003) (78)
- The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. (1997) (77)
- PET cancer evaluations with FDG. (1991) (77)
- The role of positron emission tomography in oncology and other whole-body applications. (1992) (75)
- Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. (2000) (75)
- MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma (2002) (71)
- In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. (1996) (70)
- Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. (2015) (68)
- Chronic lymphocytic leukemia and the central nervous system (1996) (67)
- Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade)1 (2006) (67)
- Role of iron in optimizing responses of anemic cancer patients to erythropoietin. (1999) (63)
- Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. (2018) (63)
- Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations (2017) (62)
- Hemostatic abnormalities in multiple myeloma and related disorders. (1992) (61)
- Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). (2019) (60)
- Erythropoietin in cancer patients. (2009) (60)
- Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. (2021) (57)
- Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. (2000) (56)
- Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. (2002) (55)
- Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. (2018) (55)
- Organochlorine pesticide content of breast adipose tissue from women with breast cancer and control subjects. (2000) (54)
- Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. (2003) (54)
- High-molecular weight iron dextran: a wolf in sheep's clothing? (2008) (54)
- Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice (2016) (53)
- Use of positron emission tomography in oncology. (1993) (52)
- Results of a multicenter, randomized, double‐blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma (2009) (51)
- CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. (2001) (51)
- Are there clinical benefits with early erythropoietic intervention for chemotherapy‐induced anemia? (2006) (51)
- A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial (2019) (50)
- Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). (2009) (50)
- Anemia and fatigue in cancer patients (2001) (50)
- Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. (1999) (49)
- Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204) (2021) (48)
- Relationship between human T cell leukemia virus-II and atypical hairy cell leukemia: a serologic study of hairy cell leukemia patients. (1987) (47)
- Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies (2015) (47)
- Positron Emission Tomography Diagnosis Of Pulmonary Metastases In Osteogenic Sarcoma (1994) (46)
- Neutropenia in an extremely premature infant treated with recombinant human granulocyte colony-stimulating factor. (1991) (46)
- 5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) (2009) (45)
- Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells (1999) (44)
- Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays (2006) (43)
- Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. (2000) (43)
- Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation (2000) (43)
- Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection. (1990) (43)
- Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. (2002) (42)
- A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial (2016) (42)
- Production of functional myeloid cells from CD34‐selected hematopoietic progenitor cells using a clinically relevant ex vivo expansion system (1994) (42)
- Megakaryocyte growth and development factor (MGDF) moderately enhances in-vitro platelet aggregation. (1995) (42)
- The effects of a high‐fat meal on single‐dose vemurafenib pharmacokinetics (2014) (41)
- Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (2012) (41)
- Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment (1997) (39)
- Granulocyte colony-stimulating factor (G-CSF): preclinical and clinical studies. (1992) (39)
- Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. (2005) (39)
- Clinical benefits of epoetin alfa therapy in patients with lung cancer. (2002) (38)
- Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion (2012) (38)
- Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. (2000) (37)
- Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. (2002) (37)
- Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. (1999) (37)
- Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review (2020) (35)
- Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC). (2009) (35)
- Thalidomide and chemotherapy combination. (1997) (34)
- Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer (2020) (34)
- Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells (2005) (34)
- Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma (2010) (34)
- Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer. (2010) (33)
- Hyperammonemia following allogeneic bone marrow transplantation (1991) (33)
- Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma (2005) (32)
- Erythropoiesis-stimulating agents in oncology. (2008) (32)
- Erythropoietins should be used according to guidelines. (2008) (31)
- A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia (2014) (31)
- Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. (1993) (29)
- Status of high-dose chemotherapy for breast cancer: a review. (2000) (28)
- Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells1 (2004) (28)
- Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy (2012) (27)
- Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. (2002) (26)
- Novel Interactions of Vitamin E and Estrogen in Breast Cancer (2005) (26)
- Standards of care for anemia management in oncology (2002) (25)
- Can Erythropoietin Therapy Improve Survival? (2004) (25)
- Positron emission tomography scanning in cancer. (1994) (25)
- Clinical trials of myeloid growth factors. (1990) (24)
- Cancer patient survival and erythropoietin. (2005) (24)
- A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: Response and cardiotoxicity. (2006) (23)
- Clinical applications of the myeloid growth factors. (1989) (23)
- Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study (2021) (23)
- Results of a multicenter, randomized, double‐blind, dose‐evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma (2009) (23)
- Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. (1999) (23)
- Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy (1999) (21)
- Hematopoietic management in oncology practice. Part 1. Myeloid growth factors. (2003) (21)
- Update on safety of ESAs in cancer-induced anemia. (2012) (21)
- Clinical applications of stem cell factor (1996) (21)
- Current Status of Use of Erythropoietic Agents in Cancer Patients (2014) (21)
- The development of erythropoietic agents in oncology (2005) (20)
- A careful reassessment of anthracycline use in curable breast cancer (2021) (20)
- Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. (2013) (20)
- The potential for anemia treatment to improve survival in cancer patients. (2002) (20)
- Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer. (2009) (20)
- The colony-stimulating factors: biology and clinical use. (1990) (19)
- A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. (2007) (19)
- Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. (2007) (18)
- The UCLA experience with type I interferons in hairy cell leukemia. (1987) (18)
- Randomized, active-controlled, phase , dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors (2001) (18)
- Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial. (2016) (17)
- The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma (2003) (17)
- A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer. (2016) (17)
- Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB) (2019) (17)
- T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human a Fetoprotein (2001) (17)
- Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. (2004) (17)
- Acupuncture: evidence and implications for cancer supportive care. (2001) (16)
- Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. (2009) (16)
- Whole body FDG PET imaging for staging of malignant melanoma: Is it cost effective? (1994) (16)
- Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients. (2018) (16)
- Anaemia Management Strategies: Optimising Treatment Using Epoetin Beta (NeoRecormon®) (2005) (16)
- High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. (2000) (16)
- Pharmacokinetics of Histamine Dihydrochloride in Healthy Volunteers and Cancer Patients: Implications for Combined Immunotherapy with Interleukin‐2 (2002) (15)
- A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors (2021) (15)
- Adult‐onset cyclic neutropenia responsive to cyclosporine therapy in a patient with ankylosing spondylitis (1993) (15)
- Relationship between omega-3 and omega-6 fatty acid ratios and breast cancer. (1997) (15)
- Cost health literacy as a physician skill-set: the relationship between oncologist reported knowledge and engagement with patients on financial toxicity (2020) (15)
- Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene–modified dendritic cell vaccines (2002) (15)
- Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA) (2005) (14)
- A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. (2013) (14)
- Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma (2016) (14)
- Impact of epoetin alfa in chemotherapy-associated anemia. (1998) (14)
- The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. (1991) (13)
- Hairy-cell leukemia: biology and treatment. (1986) (13)
- A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST). (2019) (13)
- High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. (2014) (13)
- Evolving therapy of hairy cell leukemia (1987) (13)
- Open-label, phase dose escalation study of NESP in patients with chronic anemia of cancer (2001) (12)
- Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. (2002) (12)
- Treatment of Hairy Cell Leukemia with Granulocyte Colony‐Stimulating Factor and Recombinant Consensus Interferon or Recombinant Interferon‐Alpha-2b (1992) (12)
- NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. (2022) (12)
- Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy (2007) (12)
- Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007 (2008) (11)
- Economic outcomes associated with the use of hematopoietic growth factors. (1995) (11)
- Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome (2021) (11)
- Recombinant beta‐serine‐interferon in hairy cell leukemia compared prospectively with results with recombinant alpha‐interferon (1989) (11)
- Corrections to "Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines". (2018) (11)
- A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). (2010) (11)
- Opportunistic infections in oncologic patients. (1996) (11)
- Cost considerations in therapy with myeloid growth factors. (1993) (11)
- Biology and clinical potential of stem-cell factor (1996) (11)
- Hematopoietic Management in Oncology Practice (2003) (10)
- Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON‐IDA/NEPHRO trials (2020) (10)
- 1120 POSTER Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA) (2007) (10)
- Title Combination therapy with vemurafenib ( PLX 4032 / RG 7204 ) and metformin in melanoma cell lines with distinct driver mutations (2011) (10)
- Hematopoietic management in oncology practice. Part 2. Erythropoietic factors. (2003) (10)
- Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial (2019) (9)
- Basic principles of positron emission tomography in oncology: quantitation and whole body techniques. (1994) (9)
- Initiation of epoetin‐α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy (2009) (9)
- Improvement in haemoglobin levels improves health-related quality of life (HRQOL) of anaemic cancer patients (2001) (9)
- Disturbances in hemostasis in patients with B-cell malignancies. (1992) (9)
- Methodological Issues in Trials of Acupuncture—Reply (2001) (9)
- Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis (2003) (9)
- Broad antitumor protection by dendritic cells administered to CD8α knock out mice (2006) (8)
- Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. (2013) (8)
- Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects. (2017) (8)
- Hematology: ESAs to treat anemia—balancing the risks and benefits (2009) (8)
- The clinical application of recombinant erythropoietin in the HIV-infected patient. (1994) (8)
- Consensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint. (1997) (8)
- Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. (2009) (8)
- An animal model for in vivo evaluation of tumor glycolytic rates with positron emission tomography (1993) (8)
- Workup of anemia in cancer. (2020) (8)
- Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapy. (2003) (8)
- Establishing a Denominator for Palliative Care Quality Metrics for Patients with Advanced Cancer. (2018) (8)
- Phase III clinical trials with darbepoetin: implications for clinicians. (2005) (7)
- Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. (2018) (7)
- Chemotherapy-induced anemia: the story of darbepoetin alfa (2013) (7)
- Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer (2010) (7)
- Intravenous iron in chemotherapy and cancer-related anemia (2012) (6)
- Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency. (2002) (6)
- Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. (2004) (6)
- Clinical applications of filgrastim and stem cell factor in vivo and in vitro. (1994) (6)
- 1 PD-1 blockade expands intratumoral T memory cells (2016) (6)
- Changes in Intratumoral Immune Cell Infiltrates, Foxp3 and Indoleamine 2, 3-Dioxygenase (IDO) Expression With the CTLA4 Blocking MAB CP-675,206 (2006) (6)
- Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? (2009) (6)
- Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab. (2006) (6)
- Eltrombopag, a novel, oral platelet growth factor, increases platelet counts in thrombocytopenic patients and healthy subjects. (2006) (5)
- Financial Toxicity From Generic Specialty Drug Use. (2020) (5)
- Abstract CT011: Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies (2016) (5)
- A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON‐EXT trial (2020) (5)
- High-Dose Vincristine Sulfate Liposome Injection (Marqibo®) Is Not Associated With Clinically Meaningful Hematologic Toxicity (2013) (5)
- 568 Phase I studies with CERA (Continuous Erythropoiesis Receptor Activator), an innovative erythropoietic agent (2003) (5)
- Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence (2021) (5)
- Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis (2021) (5)
- Overcoming Barriers to Erythropoietic Therapy (2002) (5)
- 489 Bevacizumab (BV) in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer (mBC): PFS subgroup results from two phase III studies (2010) (5)
- Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane (2021) (5)
- Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels (2020) (4)
- Selective and Nonselective Replication of an E 1 B-deleted Adenovirus in Hepatocellular Carcinoma 1 (1999) (4)
- 317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies (2015) (4)
- 433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial (2020) (4)
- PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First‐Line ± Standard‐of‐Care Therapies in Advanced NSCLC: Topic: Medical Oncology (2016) (4)
- Diagnosis, treatment, and use of intravenous iron for chemotherapy-induced anemia in Europe. (2011) (4)
- Long term Survival with CTLA-4 blockade Using Tremelimumab (2016) (4)
- Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective (2008) (4)
- 1129TiPA PHASE 1B/2, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TALIMOGENE LAHERPAREPVEC (T-VEC) AND IPILIMUMAB (IPI) VERSUS IPI ALONE IN PREVIOUSLY UNTREATED, UNRESECTED, STAGE IIIB, IIIC, AND IV MELANOMA. (2014) (4)
- Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma (2008) (4)
- The Impact of Therapy (Recombinant Granulocyte (1993) (4)
- 34 – Disorders of Blood Cell Production in Clinical Oncology (2014) (3)
- Nutritional, hormonal, and environmental mechanisms in breast tumorigenesis. (1996) (3)
- Empirical Criteria for the Selection of Quality-of-Life Instruments for the Evaluation of Peripheral Blood Progenitor Cell Transplantation (1998) (3)
- Current Practice In Diagnosis and Treatment of Chemotherapy-Induced Anemia In Five European Countries – A Patient Record Study (2010) (3)
- Phase III Studies of Bevacizumab (B) in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC): Summary of Selected Adverse Events. (2009) (3)
- Thrombosis during therapy with erythropoiesis stimulating agents in cancer (2008) (3)
- 1104 POSTER Patient-level integrated analysis of data from 6 randomized, double-blind, placebo-controlled trials of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA) (2007) (3)
- Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. (2021) (3)
- The impact of timing of chemotherapy relative to darbepoetin alfa (DA) on DA pharmacokinetics (PK) and hematologic effects (2004) (3)
- Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein. (2001) (3)
- A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy (2014) (3)
- [Whole body positron emission tomography in breast cancer]. (1993) (3)
- 548 CERA (Continuous erythropolesis receptor activator) is an innovative erythropoietic agent with an extended serum half-life: studies of mode of action, pharmacokinetics and erythropoietic activity (2003) (3)
- 1734PDAnti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients (2017) (3)
- The Effect of Hemoglobin (Hb) Level at ESA Initiation on Outcomes in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA): A Patient-Based Meta-Analysis from 6 Randomized, Placebo-Controlled Trials (RCTs) of Darbepoetin alfa (DA). (2007) (3)
- MACROCYTIC anemias. (1990) (3)
- Histamine dihydrochloride administered with interleukin-2 increases survival duration in patients with ocular melanoma with liver metastases (2001) (3)
- Current Deve lopments in Cancer Vacc ines and Cel lu lar Immunotherapy (2003) (2)
- Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States (2020) (2)
- The promise of colony-stimulating factors in clinical practice. (1990) (2)
- Transduction of murine and human tumors using recombinant adenovirus vectors (2006) (2)
- Darbepoetin alfa administered at varying intervals compared with weekly epoetin alfa for treating chemotherapy-induced anemia: A pooled analysis of 20 clinical trials. (2006) (2)
- Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy. (2009) (2)
- Hematologic supportive care of the critically ill cancer patient. (2000) (2)
- PCN17 COMPARING THE COST-EFFECTIVENESS OF 3 MCG/KG Q2W DARBEPOETIN ALFA WITH STANDARD DOSE EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES (2002) (2)
- Adherence to anemia treatment guidelines in U.S. community oncology practices (2007) (2)
- Factors associated with physician attitude and management of financial toxicity. (2019) (2)
- Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed? (2022) (2)
- Impact of the Covid-19 pandemic on medical oncology utilization at a busy urban academic medical center (2020) (2)
- Early and Standard Intervention with Epoetin Alfa (PROCRIT®) 120,000 Units (U) Every Three Weeks (Q3W) in Patients with Cancer Receiving Chemotherapy - Results of a Planned Interim Analysis. (2006) (1)
- Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia. (2006) (1)
- Engaging Oncologists Toward Integrating a Shared Mental Model (SMM) for Palliative Oncology within a Large Academic Oncology Practice (TH341B) (2018) (1)
- Advances in the Management of Chemotherapy-Induced Anemia and Its Treatment (2006) (1)
- Abstract 342: Development and characterization of a novel anti-CLDN6 antibody drug conjugate for the treatment of CLDN6 positive cancers (2022) (1)
- Erythropoietic therapy in the practice of oncology (2003) (1)
- Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson. (2011) (1)
- Patterns of Care in Patients with Chemotherapy Receiving Erythropoiesis Stimulating Agents (ESAs). (2007) (1)
- Phase IV evaluation of clinical outcomes of PROCRIT in anemic cancer patients receiving chemotherapy (1994) (1)
- Positive Early Breast Cancer : Results from the BCIRG Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Health-Related Quality of Life With Adjuvant Docetaxel (2013) (1)
- Survival in patients with locally advanced breast cancer after neoadjuvant docetaxel (T), carboplatin (C), and trastuzumab (H). (2009) (1)
- Are there clinical benefits associated with treatment of mild chemotherapy-induced anemia (CIA)? A systematic review (2005) (1)
- A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer. (2014) (1)
- 476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1 (2010) (1)
- Use of Erythropoiesis-stimulating Agents (ESAs) in Lung Cancer Patients: Study-level and Patient-level Meta-analyses of Safety Outcomes (2010) (1)
- Meta-analysis of the effects on safety of front-loading (FL), every-2-week (Q2W), and Q3W dosing of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA). (2012) (1)
- Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies (2022) (1)
- Abstract PO-023: Impact of the Covid-19 pandemic on medical oncology utilization at a busy urban academic medical center (2020) (1)
- Abstract CT103: Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors (2021) (1)
- 249: Inhibitory Effect of Dietary Fish Oil (Omega-3 Fatty Acids) on Human Prostate Cancer Progression in Severe-Combined Immunodeficient Mice (2005) (1)
- 1330TiPA PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL OF DENOSUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER. (2014) (1)
- Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. (2022) (1)
- Randomized controlled trials of the erythroid-stimulating agents in cancer patients. (2011) (1)
- Initiating epoetin alfa (EPO) 120,000 U every three weeks (Q3W) in pts with chemotherapy (CT)-induced anemia (CIA) (2007) (1)
- A digital oncology patient-reported outcomes platform: Building innovative electronic patient symptom assessments in epic mychart to improve the quality of life and survival of patients with advanced cancer. (2019) (1)
- A methods study to define the performance specifications of MHC tetramer assays for immune monitoring of tumor immunotherapy. (2004) (1)
- Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia (2008) (1)
- Every-three-week erythropoietic support during chemotherapy for cancer: current status and future issues. (2005) (1)
- lymphoproliferative disorders cell patient with "atypical" hairy cell leukemia: evidence for distinct T and B Integrated human T-cell leukemia virus II genome in CD8 + T cells from a (2011) (1)
- Cost-health literacy training in fellowship: A QI initiative. (2020) (1)
- Darbepoetin alfa given once every 3 weeks (Q3W) either synchronously or asynchronously with Q3W chemotherapy (ctx) improves anaemia in patients with breast cancer: results of a randomised, open-label study (2004) (1)
- 469 Incidence of selected adverse events (AEs) in phase III studies of bevacizumab (BV) in combination with chemotherapy for the treatment of HER2-negative metastatic breast cancer (mBC) (2010) (1)
- Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials. (2009) (1)
- Clinical Advantages of Neoadjuvant Docetaxel (T) and Carboplatin (C) ± Trastuzumab (H) in Locally Advanced Breast Cancer (LABC). (2009) (1)
- 1139 POSTER Treatment patterns and patient characteristics associated with treatment for chemotherapy-induced anaemia in community-based oncology practices in the U.S. (2007) (1)
- Cost-Health Literacy as an Educational Objective in Fellowship Training (2021) (0)
- Erythropoiesis-Stimulating Agents and the Practice of Gynecologic Oncology (2008) (0)
- Abstract OT2-02-05: A randomized trial of abemaciclib in combination with fulvestrant compared to chemotherapy in women with HR+, HER2- advanced breast cancer with visceral metastases (2020) (0)
- A Phase III, Randomized, Multi-Center, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627, a Novel G-CSF, in Women with Breast Cancer Receiving Myelotoxic Chemotherapy (2021) (0)
- Abstract PO-089: The impact of Covid-19 on public generosity toward cancer-related crowdfunding efforts (2020) (0)
- Abstract B86: Radiation and TGFβ blockade bring back memories in metastatic breast cancer patients (2017) (0)
- Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC). (2023) (0)
- Abstract PO-011: CiRCL: A psychosocial program facilitating communication and care to patients, families, and frontline health care teams during COVID-19 (2020) (0)
- Current D evelopments i n C ancer V accines a nd Cellular I mmunotherapy (2003) (0)
- Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer. (2023) (0)
- Introduction (2001) (0)
- zidovudine factor and erythropoietin decreases hematologic toxicity from Combined therapy with recombinant granulocyte colony-stimulating (2011) (0)
- Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion (2012) (0)
- Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort (2021) (0)
- Patients (pts) with solid tumors or lymphoproliferative malignancies (lympho) have similar dose response to darbepoetin alfa (2002) (0)
- Reviews and Notes: Oncology: Clinical Oncology (1996) (0)
- Shaping the Immune Landscape in Irradiated Breast Cancer Patients with Systemic TGF-β Blockade (2016) (0)
- Preclinical and clinical trial results using Talazoparib and Low-Dose Chemotherapy. (2022) (0)
- FRONT-LOADING WITH DARBEPOETIN ALFA PRODUCES OBSERVED IMPROVEMENTS IN HEMOGLOBIN RESPONSE AND HEALTH-RELATED QUALITY OF LIFE COMPARED WITH RECOMBINANT HUMAN ERYTHROPOIETIN (2003) (0)
- Gemcitabine/Nab-Paclitaxel and Pamrevlumab in Locally Advanced Pancreatic Cancer (LAPC): A Phase 1/2 Trial (2019) (0)
- Abstract 332: Development of a novel therapeutic CLDN18.2 monoclonal antibody and antibody drug conjugate for the treatment of CLDN18.2 positive cancers (2022) (0)
- A provider-focused, point-of-care technology to improve clinical trial accrual. (2020) (0)
- Stem Cell Factor (2000) (0)
- Precision Oncology and Nutrition (2021) (0)
- REDUCING ANEMIA AND FATIGUE IMPROVES PRODUCTIVITY IN PATIENTS WITH SOLID TUMORS (2003) (0)
- Abstract 4044: Development of UCT-01-097, a novel orally available ERK1/2 inhibitor for the treatment of ERK1/2 dependent cancers (2023) (0)
- T Cell Responses to Alpha Fetoprotein-Derived Immunodominant Peptide-Pulsed Dendritic Cells in Patients with Hepatocellular Cancer (2004) (0)
- Holter monitor cardiac safety evaluation of vincristine sulfate liposomes injection (VSLI) administered to humans with active cancer. (2011) (0)
- Assessment of Clinical Outcomes Following Erythropoietic Intervention at a Hemoglobin Concentration above 10 g/dL: A Comprehensive Review of Recent Literature. (2004) (0)
- DENDRITIC CELLS AND VACCINES Treatment ofMetastatic Colorectal Cancer Patients with a Tumor Lysate Pulsed Dendritic Cell Vaccine: A Randomized Evaluation of Ex Vivo CD40L Activation (2004) (0)
- Interaction of expectation on acupuncture as an antiemetic treatment (2010) (0)
- Long-term risks of increased use of intravenous iron – Authors' reply (2007) (0)
- MONITORING CHANGES IN GLUCOSE METABOLISM IN LIVER MELANOMA METASTASES SEQUENTIALLY TREATED WITH GM-CSF AND CYCLOPHOSPHAMIDE WITH FDG PARAMETRIC IMAGING AND PET (1992) (0)
- Updates on SABCS 2003 Abstracts (2004) (0)
- Adenovirus Lymphocytes by Dendritic Cells Transduced Generation of Melanoma-Specific Cytotoxic T (1998) (0)
- Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors. (2023) (0)
- Nivolumab Treatment of Burkitt Lymphoma: A Case Report (2020) (0)
- Abstract P6-13-03: Not presented (2019) (0)
- Can We Define the Mechanism of Antitumor Response Observed During Clinical Adoptive Immunotherapy (1997) (0)
- Risks for Anaphylaxis With Intravenous Iron Formulations (2022) (0)
- Cells in the Absence of CD8-Positive Cells Enhanced Tumor Responses to Dendritic (2013) (0)
- How Might ESAs Alter Cancer Biology , Response to Treatment , or Survival ? (2009) (0)
- Epoetin alfa improves hemoglobin levels and quality of life for lung cancer patients receiving chemotherapy (2000) (0)
- Exceptional Response to Erda fi tinib in FGFR2 -Mutated Metastatic Pancreatic Ductal Adenocarcinoma (2022) (0)
- Objective Radiographic Response to MEK Inhibitor Therapy in a Patient with a Metastatic Melanoma with a BRAF (2012) (0)
- Cancer Therapy: Clinical Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma (2009) (0)
- Melanoma and sarcoma (2005) (0)
- A careful reassessment of anthracycline use in curable breast cancer (2021) (0)
- TCRM_A_243462 245..259 (2020) (0)
- Author reply (0)
- Cytokines in the Supportive Care of Cancer (2007) (0)
- Encore Abstracts (2007) (0)
- Society News June 2005 (2005) (0)
- The UCLA-Community Breast Cancer Collaborative Clinical Translational Research Program (2002) (0)
- Evaluating if darbepoetin alfa efficacy and safety in patients with chemotherapy-induced anemia is affected by the disease stage of the patient. (2016) (0)
- Safety profile of histamine dihydrochloride administered with interleukin-2 in patients with advanced metastatic malignant melanoma (2001) (0)
- 1417: Growth Inhiditory Effects of a Low-Fat Diet on Prostate Cancer Cells in Vitro: Results of a Prospective Randomized Dietary Intervention Trial in Men with Prostate Cancer (2005) (0)
- Standardization of MHC Tetramer and ELISPOT Assays To Quantitate Antigen-Specific T Cell Expansion after CTLA4 Blockade (2004) (0)
- Initiating epoetin-alpha (EPO) 120,000 units (U) every three weeks (Q3W) in patients with chemotherapy (CT)-induced anemia (CIA) and a hemoglobin (Hb) of <11 g/dL (2007) (0)
- Implementation and dissemination of a shared mental model of palliative oncology. (2019) (0)
- Evaluating the Safety of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Breast Cancer, Lung Cancer, and Hematologic Malignancies: A Meta-Analysis of Randomized, Controlled Trials. (2007) (0)
- 233 A phase IV study of epoetin alfa examining clinical outcomes in anaemic cancer patients receiving chemotherapy (1995) (0)
- Commentary (Glaspy)—Thrombopoietin: Biology and Potential Clinical Applications (1998) (0)
- cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. (2011) (0)
- Management of Anemia in Patients With Cancer (2002) (0)
- Neoadjuvant docetaxel (T), carboplatin (C), with or without trastuzumab (H) for T3 and T4 breast cancer (2005) (0)
- Multicenter P hase I I S tudy o f O ral B exarotene f or P atients With M etastatic B reast C ancer (2003) (0)
- PCN5 COMPARING THE COST-EFFECTIVENESS OF FRONT-LOADED DARBEPOETIN ALFA WITH EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES (2002) (0)
- Retroviral diseases in hematology. (1994) (0)
- WEEKLY DARBEPOETIN ALFA DOSES OF 2.25 AND 4.5 MCG/KG PRODUCE HIGHER OBSERVED MEAN HEMOGLOBIN CHANGES THAN THREE TIMES WEEKLY RECOMBINANT HUMAN ERYTHROPOIETIN AT 150 OR 300 U/KG (2003) (0)
- Anemia and Red Cell Factors (2008) (0)
- WHOLE-BODY PET WITH FDG FOR DETECTION OF BOTH PRIMARY AND METASTATIC MALIGNANCIES: AN UPDATE OF THE CLINICAL EXPERIENCE (1992) (0)
- Entering a new era in the management of tumor-associated involution. (2005) (0)
- Evaluation of Hematologic Endpoints Used To Assess Erythropoiesis-Stimulating Agents (ESAs): A Pooled Analysis of Data from over 10,000 Patients (pts) with Chemotherapy-Induced Anemia (CIA). (2006) (0)
- Author reply (0)
- Abstract OT-13-01: A phase I study of preoperative ipilimumab, nivolumab, and talimogene laherparepvec for localized breast cancer (2021) (0)
- Engaging oncologists toward integrating a shared mental model for palliative oncology within a large academic oncology practice. (2017) (0)
- Economic Outcomes Associated With Hematopoietic Growth Factors (1995) (0)
- CiRCL: A psychosocial program facilitating communication and care to patients, families, and frontline health care teams during COVID-19 (2020) (0)
- Identifying resources available to physicians for management of financial toxicity: A Fellow-driven QI initiative. (2020) (0)
- Evaluation of cancer detection with whole-body positron emission tomography (PET) and 2-[F-18]fluoro-2-deoxy-D-glucose (1993) (0)
- iSABR: Safety and Efficacy Results from a Phase II Study of SABR in Combination with Durvalumab for Early-Stage Medically Inoperable NSCLC (2022) (0)
- Characterization of Melanoma Antigen-Specific T Cells in a Long Term Survivor with Metastatic Melanoma with a Stable Peripheral Blood Population of Greater Than 5% of MART-1-Specific CD8+ T Cells (2004) (0)
- Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial (2023) (0)
- Abstract 5991: Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With John A. Glaspy?
John A. Glaspy is affiliated with the following schools: